Blood (ASH) 'Under Review': What Each Status Means and When to Expect a Decision
If your Blood submission shows Under Review, here is what the ASH editors are doing during each stage and when to follow up.
While you wait
Waiting on Blood? Get your next move ready.
The Blood wait is out of your hands; the next move isn't. Scan your next manuscript free, or run this paper through the scan to see what reviewers typically push back on, so the revision response is ready when the decision lands.
Last reviewed: 2026-10-08.
Quick answer: If your Blood submission shows "Under Review," elapsed time is the most reliable signal. Blood has a 2025 Journal Impact Factor of 23.9 in the 2026 JCR release, and ASH says manuscripts that pass editor screening are reviewed by editorial-board members or outside experts. Blood can rapidly reject papers without external review when they are uncompetitive or outside scope, so Under Review usually means the editor is evaluating fit or collecting expert reports.
What should Blood authors check first?
For a second opinion before reviewers see your manuscript, run a Blood submission readiness check.
Related Manusights pages: Blood journal overview, Blood submission guide, Blood review time, and Blood formatting requirements.
Submission portal and editorial contact: Blood uses eJournalPress at the Blood submission portal. Editorial questions should reference the manuscript number and go to the Blood editorial office (editorial@hematology.org); presubmission inquiries go through the online submission system or to bloodeditor@hematology.org.
The Blood manuscript submission portal and the Blood peer-review-process page cover the editorial workflow and status-check guidance. For broader status-tracking guidance across publishers, the Cell Press author status portal gives useful baseline patterns for reading status fields across editorial portals.
What does ASH do after a Blood manuscript goes Under Review?
ASH says manuscripts that have passed initial screening by the Editors are reviewed by members of the Editorial Board and/or other experts in the field, and that the Editors select the reviewers and make the final decision. The Blood Journals peer review process is single-anonymized: reviewers remain unknown to the authors, while the authors are known to the reviewers.
At the discretion of the journal's Editors, a manuscript may be rapidly rejected without external peer review if it is deemed uncompetitive or outside the scope of the journal. Most articles are rejected on grounds of insufficient priority or lack of relevance to hematology, not data quality or technical issues.
Blood editorial culture is decisive: scope misfit and framing problems drive most early rejections, not weak methodology. Papers that pass the Blood editor desk screen have cleared the steepest filter in ASH hematology publishing.
What does each Blood stage mean?
The ASH author pages we reviewed do not list the status labels shown in the submission system. The table below maps the stages ASH does describe to what is happening, with ASH's own timing figures where it publishes them.
Stage | What is happening | Timing ASH publishes |
|---|---|---|
Submission in progress | The submission must be completed before peer review can begin; you receive a confirmation e-mail with the manuscript number | 30 days to complete a started submission; partial submissions are then deleted |
Editor screening | The Editors screen for competitiveness and scope and may reject without external review | ASH reports an average of 15 days from submission to first decision (unsolicited submissions) |
External review | At least 2 (typically 3) external experts selected by the Editors review the paper | No published per-stage duration |
Decision | The Editors make the final decision; reviewers recommend Accept, Reject, Major Revision needed, or Minor Revision needed | Included in the 15-day average to first decision |
Revision | Major revision: new data should be obtainable within 3 months; minor revision: relatively simple changes, about 1 month | Revised manuscripts are due within 3 months of the decision e-mail |
Acceptance to First Edition | Accepted papers are published ahead of print as First Edition papers | 11 days on average (unsolicited submissions) |
The Blood editor desk screen
Before the paper reaches external reviewers, the Editors evaluate whether it is competitive and within scope. ASH says all manuscripts are judged in relation to other submissions currently under consideration, and we found no desk-rejection rate on ASH's Blood author pages.
A desk rejection most often means the Editors concluded that the hematology-priority bar is not met. ASH says most articles are rejected on grounds of insufficient priority or lack of relevance to hematology, not data quality or technical issues. If the work is sound but below Blood's bar, the Blood Journals portfolio includes Blood Advances and five other journals, and authors can opt in at submission to transfer a manuscript that is not accepted.
Administrative processing
ASH says the submission process must be successfully completed before peer review can begin. A successful submission is acknowledged by an e-mail to the corresponding author with the manuscript number, and all coauthors receive an automated confirmation e-mail. The package ASH lists includes the abstract and manuscript files (with page numbers), the cover letter to the Editor-in-Chief, suggested reviewers if any, and payment of the submission fee for Regular Articles and Brief Reports. Clinical trials must be registered before enrollment, and original research needs a data sharing statement. ASH publishes no duration for this stage.
Editor screening
The Editors read the paper and evaluate it against ASH's primary criteria: quality, novelty, and scientific importance, together with priority for publication, presentation of the material, and relevance to the journal's general readership.
Portfolio transfer for papers that are not accepted
Authors can opt in at submission to transfer a manuscript that is not accepted to another journal in the Blood Journals portfolio, and Blood Journals staff will also help transfer a rejected submission on request (editorial@hematology.org). All available editor notes and peer reviewer reports transfer with the manuscript files. Manuscripts cannot be transferred to Blood from the other portfolio journals.
External reviewer recruitment
Manuscripts that pass initial screening are reviewed by at least 2 (typically 3) external experts in the field, and the Editors select the reviewers. ASH publishes no recruitment window.
Active peer review
Reviewers are asked whether the methods are adequate and appropriate, whether the conclusions are justified by the data, and whether the results are sufficiently important and novel to advance the field. They recommend Accept, Reject, Major Revision needed, or Minor Revision needed. ASH publishes no reviewer deadline on its author pages.
Editorial synthesis and decision
After reports return, the Editors make the final decision. ASH says accepted papers go through no more than 2 rounds of revision on average. First decisions can move quickly when scope and reviewer matching are straightforward, but complex or specialized papers can take longer.
When to worry about Blood Under Review
- Rejection within days: Most likely a quick editorial rejection without external review for scope or priority, which ASH says the Editors may do at their discretion.
- Still Under Review well beyond ASH's 15-day average to first decision: Not necessarily bad. The average covers all first decisions, and ASH publishes no per-stage window for papers that go to external review.
- Still Under Review after 10 weeks: Reviewer-recruitment or reviewer-report delay is possible. A polite inquiry to the Blood editorial office (editorial@hematology.org), quoting your manuscript number, is appropriate.
- A decision e-mail arrives: Read the decision letter closely; revised manuscripts are due within 3 months of that e-mail.
"My paper has been Under Review for 8 weeks. Is that bad?"
This is the most common anxiety we hear from Blood authors during the active editorial window. The honest answer: not necessarily. ASH publishes a 15-day average from submission to first decision across unsolicited submissions, not a distribution for papers that go to external review, so 8 weeks does not by itself signal a problem. Reports may already be in editorial synthesis.
Reviewer availability is a common cause of delay at any journal, but ASH publishes no data on it for Blood. If the portal still says Under Review at the 10-week mark, a single concise inquiry is reasonable.
What you should NOT do during the 8-to-10-week window is send repeated status e-mails to the editorial office. One inquiry with your manuscript number is enough.
What should you do while waiting?
- Do not email the editorial office during the first 6 weeks unless an urgent ethics issue surfaces.
- Do not submit the paper anywhere else while it is Under Review at Blood. ASH has explicit prohibitions on dual submission.
- Prepare a point-by-point response template for likely reviewer concerns: hematology-significance, scientific rigor, CONSORT compliance, reproducibility.
- If you have related work submitted elsewhere or recently published, prepare disclosure language for when revisions are requested.
- Read recent Blood research articles in your subfield to calibrate the current editorial bar.
Readiness check
While you wait on Blood, scan your next manuscript.
The scan takes about 2 to 3 minutes. Use the result to decide whether to revise before the decision comes back.
If Blood rejects: sister-journal cascade with reasoning
If your Blood paper is rejected after review, the natural cascade depends on what the reviewers and editor cited:
Blood Advances is the natural ASH cascade for clinical-research hematology papers where the priority bar of Blood flagship is not met but the rigor is high. ASH supports manuscript transfer with editor notes and reviewer reports preserved.
Blood Cancer Discovery is the cascade for cancer-research hematology papers, but it is not part of ASH's Blood Journals portfolio (it is an AACR journal), so a transfer from Blood does not apply.
Blood Cancer Journal is an open-access hematology-cancer option outside ASH's Blood Journals portfolio, so it also needs a fresh submission.
Leukemia is the external Springer Nature hematology cascade for leukemia-focused work. Nature Portfolio operates independently from ASH; the Nature Portfolio Manuscript Tracking System at mts-leu.nature.com handles submission; leukemia@nature.com handles publisher-level inquiries.
Haematologica is the European Hematology Association journal cascade for general-hematology research.
Journal of Clinical Oncology (JCO) is the ASCO cascade for clinical-oncology hematology research (especially leukemia, lymphoma, myeloma clinical trials).
How Blood compares to nearby alternatives
Feature | Blood | Blood Advances | Leukemia (Nature) | Haematologica |
|---|---|---|---|---|
Desk-rejection rate | No ASH figure | Not published | Not published | Not published |
Desk-decision speed | ASH reports a 15-day average to first decision | 7 to 14 days | 14 to 28 days | 7 to 14 days |
Total review time (post-screen) | No ASH figure | 4 to 8 weeks | 8 to 12 weeks | 6 to 10 weeks |
Reviewer count | ≥2, typically 3 | 2 to 3 | 2 to 3 | 2 to 3 |
Peer-review model | Single-blind | ASH open-access single-blind | Single-blind, optional transparency | Single-blind |
Editorial bar | Top-tier ASH hematology priority + scope | ASH open-access clinical-research | Nature Portfolio leukemia | EHA general-hematology |
Submit if your paper passed the desk
If your Blood paper has been sent to external reviewers, you have cleared the steepest filter in ASH hematology publishing. Use the waiting window to prepare a thorough revision response template anticipating feedback from at least 2 (typically 3) reviewers.
Blood submission readiness check takes about 5 minutes.
Think Twice If
Blood senior editors retain discretion to reject after partial review if reviewer reports surface methodological or hematology-significance concerns the desk screen did not catch. The community-estimated 15 to 18 percent overall acceptance rate (an estimate, not an ASH figure) means most post-desk-screen papers still receive a reject or substantial-revision decision.
- the study uses hematology samples or cell lines but does not state the hematology consequence in the first paragraph
- the methods leave flow cytometry, single-cell, trial, or transplant-outcome adjudication details too thin for subspecialty reviewers
- the cover letter emphasizes a platform or pathway before explaining why Blood readers should care
Check your Blood reviewer-risk profile before reviewer reports surface those concerns.
Last verified: Blood peer review policies at ashpublications.org and ASH editorial documentation.
The Blood reviewer experience
ASH's reviewer instructions pose five questions: whether the methods are adequate and appropriate, whether the conclusions are justified by the data, whether the content, style, and tone are appropriate, whether the manuscript will stimulate constructive discussion, and whether the results are important and novel enough to advance the field. The table below maps those questions to four preparation areas we use.
Reviewer focus area | Related ASH reviewer question | How to prepare for it |
|---|---|---|
Hematology priority and scope | Are the results sufficiently important and novel to advance the field? ASH says Blood cannot publish articles that are technically adequate but do not advance the field in a significant way. | Frame the introduction around the broader-hematology priority the findings address. Most articles are rejected on grounds of insufficient priority or lack of relevance to hematology, not data quality. |
Scientific rigor | Are the methods employed adequate and appropriate for the questions being addressed? | Include detailed methods documentation. ASH requires clinical trials to be registered before enrollment and recommends the ARRIVE guidelines for animal studies. |
Reproducibility | Are the conclusions justified given the data presented? | Use detailed methods documentation. Blood requires data-sharing statements, and ASH asks authors to use public repositories for data whenever possible. |
Subspecialty expertise match | ASH says the Editors select the reviewers, who are Editorial Board members and/or other experts in the field | Anticipate that your subspecialty's specific reviewers will read the paper. Address subspecialty-specific methodological concerns explicitly in the methods. |
Blood status inquiry checklist
Situation | Best next step |
|---|---|
Under Review for fewer than 6 weeks | Wait and prepare a response outline around hematology priority, method detail, and data sharing. |
Under Review for 6 to 10 weeks | Confirm the manuscript ID, portal route, and corresponding-author email before contacting the office. |
Under Review for more than 10 weeks | Send one concise portal inquiry with the manuscript ID and submission date. |
Status-only anxiety with no new information | Improve the likely reviewer-response package rather than sending repeated status emails. |
What we see in Blood manuscripts
Across Blood manuscripts, we have reviewed 50+ manuscripts targeting Blood, Blood Advances, hematology, leukemia, lymphoma, myeloma, hemostasis, transplantation, and clinical hematology journals. In our pre-submission review work across hematology and translational-oncology venues, the highest-leverage factor was whether the manuscript made hematology priority unavoidable in the title, abstract, first figure, and cover letter. A technically strong paper can still look wrong for Blood if the hematology consequence is implied instead of argued.
Blood hematology-priority gap in the opening. In our pre-submission review work we see a repeated pattern where the data are serious, but the opening reads like general cancer biology, immunology, cell biology, or clinical methods work. Blood reviewers and editors need to see why the finding changes a hematology question, not merely why it uses blood, marrow, leukemia cells, or immune populations. The fix is to make the hematology consequence visible in the abstract, first paragraph, and first figure legend.
Check whether your Blood hematology-priority signal is visible →
Blood subspecialty-method detail too thin for expert review. A second pattern is a manuscript that states the right hematology question but leaves methods underexplained for the subspecialty reviewer. This often appears in flow cytometry panel design, gating strategy, single-cell processing, clinical-trial sample-size justification, transplant outcome adjudication, thrombosis endpoints, or image quantification. Stronger submissions move the audit trail into the methods and supplementary files before review begins.
Check if your Blood methods package is reviewer-ready →
Blood Advances or specialty-journal route hidden in the decision logic. A third pattern is a paper that is rigorous but not flagship-priority for Blood. If editor or reviewer comments praise the data but question general hematology importance, the author should not only ask whether to appeal. The better question is whether Blood Advances, Blood Cancer Discovery, Haematologica, Leukemia, or a subspecialty clinical venue would preserve momentum with less priority friction.
Source limitation: our observations come from Manusights pre-submission and revision-support work, not from private Blood editorial records. We do not train on private author files, and Manusights offers a 60-day money-back guarantee for eligible review orders when the service does not meet the stated scope.
Methodology note
This page was created from ASH's public peer review policies at ashpublications.org, Blood manuscript submission documentation (at-least-2 typically-3 reviewer model and priority-and-scope desk-rejection criteria), and Manusights pre-submission review experience with Blood-targeted manuscripts.
What to read next
For the ASH hematology landscape beyond Blood flagship, see Blood Advances (clinical-research open-access cascade) and the other journals in the Blood Journals portfolio, and external hematology alternatives (Blood Cancer Discovery from AACR, Blood Cancer Journal, Leukemia, Haematologica, JCO, NEJM for top-tier clinical hematology trials). The choice across these titles depends on whether the central contribution is top-tier ASH hematology priority (Blood), ASH open-access clinical-research (Blood Advances), cancer-research hematology (Blood Cancer Discovery), open-access cancer-hematology (Blood Cancer Journal), or external hematology (Leukemia, Haematologica, JCO, NEJM).
Reviewers at Blood typically draw from subspecialty experts in leukemia, lymphoma, myeloma, hemostasis, transplantation, or benign hematology. Editors screen and triage manuscripts before any external reviewer sees them, and preparing a response template that addresses subspecialty-matched methodology and broader-hematology priority accelerates revision rounds substantially.
For a pre-upload check of your manuscript against the Blood hematology-priority bar before submission, our Blood pre-submission diagnostic flags the framing and subspecialty-methodology weaknesses most likely to surface in reviewer reports.
Frequently asked questions
Your manuscript has completed submission in the Blood eJournalPress system and is being evaluated. At the discretion of the journal's Editors, a manuscript may be rapidly rejected, without external peer review, if it is deemed uncompetitive or outside the scope of the journal. Most articles are rejected on grounds of insufficient priority or lack of relevance to hematology, not data quality or technical issues.
Blood operates two tracks: rapid rejection without external review at the Editors' discretion, and full peer review. ASH reports an average of 15 days from submission to first decision for unsolicited submissions, and says manuscripts that have passed initial screening by the Editors are reviewed by at least 2 (typically 3) external experts in the field. First decisions can move quickly when scope and reviewer matching are straightforward, but complex or specialized papers can take longer.
Wait at least 6 weeks before inquiring. Contact the Blood editorial office (editorial@hematology.org) referencing your manuscript number.
Not necessarily. ASH publishes a 15-day average from submission to first decision across unsolicited submissions, not a distribution for papers that go to external review, so 8 weeks does not by itself signal a problem. Reports may already be in editorial synthesis.
Your paper passed the Editor desk screen and at least 2 (typically 3) external experts in the field have agreed to review. Blood operates single-anonymized peer review: reviewers remain unknown to the authors, while the authors are known to the reviewers.
It can be. ASH reports a 15-day average to first decision across unsolicited submissions and publishes no per-stage timetable, so a longer wait is not by itself a warning sign. ASH says accepted papers go through no more than 2 rounds of revision on average, and revised manuscripts are due within 3 months of the decision.
Past 10 weeks is a reasonable moment for a polite inquiry to the Blood editorial office. ASH publishes no per-stage timetable, so silence before then is not by itself a warning sign.
Sources
Free guide
Waiting is not the same as being ignored, and there is a way to tell.
Reviewers usually get ten days. When it has been months, an appeal and a complaint are different instruments with different addresses, and only one of them fits a delay. This is which to use, and the wording that gets an answer.
Final step
Done interpreting the status? Put the wait to work.
The Blood decision will arrive on the journal's clock. What you control is what's next: scan your next manuscript free, or run this paper through the scan so the likely reviewer pushback is mapped before the revision request lands.
Free scan, no card needed.
Target journal Blood
Private API processing. Your manuscript is not used to train models.
Re-read the status guidePut the guidance to work
Turn a decision into a clear next step.
Use the practical response workflow when a manuscript needs revision, or the process guide when you need to understand what the editorial status means.
Where to go next
Start here
Same journal, next question
- Blood Review Time: What to Expect From Submission to Decision
- Blood Submission Process: What Happens From Upload to First Decision
- How to Avoid Desk Rejection at Blood
- Is Blood a Good Journal? Impact Factor, Scope, and Submission Guide
- Blood Acceptance Rate 2026: How Selective Is the ASH Flagship?
- Rejected from Blood? The 7 Best Journals to Submit Next